Show all

AMAG Pharmaceuticals is headquartered in Waltham, Massachusetts. Our mailing address is: 1100 Winter Street, Waltham, MA 02451. Tel: 617-498-3300.
AMAG Pharmaceuticals was incorporated in Delaware in November 1981.
December 31.
Goodwin Procter LLP, 53 State Street, Boston, MA 02109, (617) 570-1000.
AMAG’s CUSIP number is 00163U106.
Please contact AMAG Pharmaceuticals' transfer agent, American Stock Transfer and Trust Company (AST), via the web using your account number at www.amstock.com or by phoning AST at 800-937-5449 or 718-921-8124.
AMAG Pharmaceuticals does not have a direct purchase program. You must purchase stock through your broker.
AMAG Pharmaceuticals is quoted on the NASDAQ Global Select Market under the ticker symbol AMAG.
On August 6, 1991, the company completed a 3-for-2 stock split.
AMAG Pharmaceuticals became a publicly traded company in 1986. It began trading on the NASDAQ Global Market under the ticker symbol “AMAG” on June 27, 2006. The Company had previously been traded on the American Stock Exchange under the trading symbol “AVM”.
AMAG Pharmaceuticals has never paid any cash dividends on our common stock and we do not anticipate paying cash dividends in the foreseeable future.
PricewaterhouseCoopers, LLP, 101 Seaport Boulevard, Boston, MA 02210, (617)-530-5000.
Additional information is available on the Investor's section of our website: www.amagpharma.com.
You may communicate with our Board of Directors by e-mailing the party or parties to whom the communication is intended at contactus@amagpharma.com or by writing to: AMAG Pharmaceuticals, Attn: Corporate Secretary, 1100 Winter Street, Waltham, MA 02451. Please contact the Board of Directors for legitimate business inquiries. Solicitations of any kind will be ignored.
AMAG Pharmaceuticals' board of directors consists of eight individuals with broad experience in business, medicine and health care. Seven of the directors are fully independent by Securities and Exchange Commission (SEC) and NASDAQ standards. Only the CEO of AMAG Pharmaceuticals, Inc. is considered a non-independent director.
Yes. The audit committee is led by Davey S. Scoon. Mr. Scoon is considered to be an independent board member as such term is defined in the listing standards of the NASDAQ Global Market and SEC rules.